Literature DB >> 19149852

Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density.

M Khawaji1, K Akesson, E Berntorp.   

Abstract

It has been previously shown that patients with severe haemophilia and not receiving any prophylactic treatment render a high risk of reduced bone mineral density. The purpose of this study was to evaluate bone mineral density (BMD) in patients with haemophilia of different severity types and treatment. The study group consisted of 26 patients with severe haemophilia (aged 33.6 +/- 2.1) and 16 patients with mild haemophilia (aged 40.2 +/- 3.3). The BMD (g cm(-2)) was measured by dual-energy X-ray absorptiometry (DXA). Physical activity was assessed by a self-report questionnaire. Physical activity was scored as duration (h week(-)) and as metabolic physical activity score by weighing the intensity (MET-h week(-1)). Joints were evaluated according to a physical examination score. There was no significant difference in BMD at lumbar spine L1-L4 (mild, 1.214 vs. severe, 1.175; P = 0.329), total hip (1.085 vs. 1.001, P = 0.114), femoral neck (1.036 vs. 0.977, P = 0.265), trochanter (0.896 vs. 0.820, P = 0.131) and whole body (1.215 vs. 1.183, P = 0.325) between those with mild and severe haemophilia. Based on Z-score, both groups had normal BMD (Z score >-1). In patients with severe haemophilia, there was a significant correlation between joint evaluation score and BMD at total hip (P < 0.0001), femoral neck (P = 0.0003) and trochanter (P = 0.003). Physical activity did not correlate to disease severity. We did not observe a correlation between BMD and severity of haemophilia. The results indicate that the use of factor prophylaxis since early childhood may preserve normal BMD in severe haemophilia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19149852     DOI: 10.1111/j.1365-2516.2008.01912.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  14 in total

Review 1.  Bleeding disorders and reduced bone density.

Authors:  Hassan Mansouritorghabeh; Zahra Rezaieyazdi
Journal:  Rheumatol Int       Date:  2010-05-27       Impact factor: 2.631

2.  Joint bleeding in factor VIII deficient mice causes an acute loss of trabecular bone and calcification of joint soft tissues which is prevented with aggressive factor replacement.

Authors:  A G Lau; J Sun; W B Hannah; E W Livingston; D Heymann; T A Bateman; P E Monahan
Journal:  Haemophilia       Date:  2014-04-08       Impact factor: 4.287

3.  Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis.

Authors:  Junjiang Sun; Baolai Hua; Eric W Livingston; Sarah Taves; Peter B Johansen; Maureane Hoffman; Mirella Ezban; Dougald M Monroe; Ted A Bateman; Paul E Monahan
Journal:  Blood       Date:  2016-12-30       Impact factor: 22.113

Review 4.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Authors:  Hans-Christoph Rossbach
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

5.  Osteoporosis in haemophilic patient, rehabilitative aspects.

Authors:  Patrizia Franco
Journal:  Clin Cases Miner Bone Metab       Date:  2012-09-30

6.  Evaluation of osteoporosis in hemophilic arthropathy patients: correlation with disease severity and serum trace minerals.

Authors:  Eiman Mahmoud Ghaniema; Sahar Fathi Ahmed; Irene Raouf Amin; Maryse Soliman Ayoub
Journal:  J Osteoporos       Date:  2011-10-05

Review 7.  Bone Density Status in Bleeding Disorders: Where Are We and What Needs to Be Done?

Authors:  Hassan Mansouritorghabeh; Zahra Rezaieyazdi
Journal:  J Bone Metab       Date:  2017-11-30

8.  Hemophilia A and B mice, but not VWF-/-mice, display bone defects in congenital development and remodeling after injury.

Authors:  Sarah Taves; Junjiang Sun; Eric W Livingston; Xin Chen; Jerome Amiaud; Regis Brion; William B Hannah; Ted A Bateman; Dominique Heymann; Paul E Monahan
Journal:  Sci Rep       Date:  2019-10-08       Impact factor: 4.379

9.  PHILEOS (haemoPHILia and ostEoporOSis) Study: protocol of a multicentre prospective case-control study.

Authors:  Brigitte Tardy-Poncet; Barbara Play; Aurélie Montmartin; Pauline Damien; Edouard Ollier; Emilie Presles; Arnauld Garcin; Bernard Tardy
Journal:  BMJ Open       Date:  2021-01-13       Impact factor: 2.692

Review 10.  Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B.

Authors:  Johnny N Mahlangu
Journal:  Ther Adv Hematol       Date:  2018-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.